Keywords: neuroinflammation, non-coding RNA, K+ channels
The research activity of Dr. Parisi’s group focuses on the role of non-coding RNAs in mechanisms related to human disease pathogenesis.
Specifically, one major aim is the study of molecular bases of neurodegerative diseases as Amyotrophic Lateral Sclerosis (ALS), focusing on microglia mechanisms of neuroinflammation related to specific pathways, as the NF-kB pathway and to microRNAs, as the miR-125b.
Additionally, the group is studying the molecular bases of some neurodevelopmental rare diseases, focusing on the role of small and long non-coding RNAs in the regulation of genes, as potassium channels and glucose carriers, involved in the pathogenesis of Zimmermann-Laband, FHEIG syndrome and GLUT1 deficiency syndromes.
Education:
2010: University of Rome “La Sapienza”: PhD degree in Human Biology and Genetics.
2006: University of Rome “La Sapienza”: Master Degree in Pharmaceutical Biotechnology (110/110 cum laude).
2004: University of Rome “La Sapienza”: Degree in Biotechnology (110/110 cum laude).
Positions:
CURRENT POSITION: Permanent Researcher position at Institute of Cell Biology and Neurobiology (IBCN)-National Research Council (CNR), Via Ercole Ramarini, 32, 00015 Monterotondo, Rome, IT.
July 2016-November 2018: Post-doctoral associate at laboratory of Neurotrophic Factors and Neurodegenerative Diseases, European Brain Research Institute (EBRI), Rome, IT.
March 2016-April 2016: COST Short Term mission. Scientific Collaborator at laboratory of Molecular Inflammation, IMIB, Murcia, Spain.
February 2011- February 2016: Post-doctoral associate at laboratory of Cellular Neurobiology, Institute of Cell Biology and Neurobiology (IBCN), National Research Council (CNR), Rome, Italy.
November 2010-February 2011: Fellowship at laboratory of Gene Silencing, European Brain Research Institute (EBRI), Rome, Italy.
November 2006-November 2010: PhD student at the laboratory of Gene Silencing, European Brain Research Institute, (EBRI), Rome, Italy.
Honours/Awards:
2015: AWARD Best Poster “Giovani per la ricerca”. Primo Simposio Nazionale sulla SLA
1: Amadio S, Parisi C, Piras E, Fabbrizio P, Apolloni S, Montilli C, Luchetti S, Ruggieri S, Gasperini C, Laghi‐Pasini F, Battistini L, Volonté C. Modulation of P2X7 Receptor during Inflammation in Multiple Sclerosis. Front Immunol. 2017 Nov 15;8:1529.
2: Parisi C, Napoli G, Pelegrin P, Volonté C. M1 and M2 Functional Imprinting of Primary Microglia: Role of P2X7 Activation and miR‐125b. Mediat Inflamm. 2016;2016:2989548.
3: Parisi C*, Napoli G, Amadio S, Spalloni A, Apolloni S, Longone P, Volonté C. MicroRNA‐125b regulates microglia activation and motor neuron death in ALS. Cell Death Differ. 2016 Mar;23(3):531‐41.
4: Parisi C, Arisi I, D’Ambrosi N, Storti AE, Brandi R, D’Onofrio M, Volonté C. Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis. 2013 Dec 12;4:e959.
5: Apolloni S, Parisi C, Pesaresi MG, Rossi S, Cozzolino M, Volontè C, D’Ambrosi N. The NADPH oxidase pathway is dysregulated by P2X7 receptor in the SOD1‐G93A microglia model of Amyotrophic Lateral Sclerosis. J Immunol. 2013 190(10):5187‐95.
1: Di Segni M, D’Addario SL, Babicola L, Ielpo D, Lo Iacono L, Andolina D, Accoto A, Lucetti A, Mancini M, Parisi C, D’Onofrio M, Arisi I, Brandi R, Pascucci T, Cifani C, D’Amato FR, Ventura R. Xlr4 as a new candidate gene underlying vulnerability to cocaine effects. Neuropharmacology 2020 . doi: 10.1016/j.neuropharm.2020.108019
2: Marinelli S, Vacca V, Angelis F, Pieroni L, Orsini T, Parisi C, Soligo M, Protto V, Manni L, Guerrieri R, Pavone F.Innovative mouse model mimicking human-like features of spinal cord injury: efficacy of Docosahexaenoic acid on acute and chronic phases.Sci Rep. 2019 Jun 20;9(1):8883.
3: Amadio S, Parisi C, Piras E, Fabbrizio P, Apolloni S, Montilli C, Luchetti S, Ruggieri S, Gasperini C, Laghi‐Pasini F, Battistini L, Volonté C. Modulation of P2X7 Receptor during Inflammation in Multiple Sclerosis. Front Immunol. 2017 Nov 15;8:1529.
4: Parisi C, Napoli G, Pelegrin P, Volonté C. M1 and M2 Functional Imprinting of Primary Microglia: Role of P2X7 Activation and miR‐125b. Mediat Inflamm. 2016;2016:2989548.
5: Parisi C*, Napoli G, Amadio S, Spalloni A, Apolloni S, Longone P, Volonté C. MicroRNA‐125b regulates microglia activation and motor neuron death in ALS. Cell Death Differ. 2016 Mar;23(3):531‐41.
6: Volonté C, Apolloni S, Parisi C, Amadio S. Purinergic contribution to Amyotrophic Lateral Sclerosis. Neuropharmacology. 2016 May;104:180‐93. IF: 5.012
7: Apolloni S, Fabbrizio P, Parisi C, Amadio S, Volonté C. Clemastine Confers Neuroprotection and Induces an Anti‐ Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis. Mol Neurobiol. 2016 Jan;53(1):518‐31.
8: Volonté C, Parisi C, Apolloni S. New kid on the block: Does histamine get along with inflammation in amyotrophic lateral sclerosis?. CNS Neurol Disord Drug Targets 2015;14(5):677‐86.
9: Volonte C, Apolloni S, Parisi C. MicroRNAs: Newcomers into the ALS Picture. CNS Neurol Disord Drug Targets. 2015;14(2):194‐207.
10: Amadio S, Parisi C, Montilli C, Carrubba AS, Apolloni S, Volonté C. P2Y12 Receptor on the Verge of a Neuroinflammatory Breakdown. Mediat Inflamm. 2014;2014:975849. doi: 10.1155/2014/975849.
11: Apolloni S, Amadio S, Parisi C, Matteucci A, Potenza RL, Armida M, Popoli P, D’Ambrosi N, Volonté C. Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1‐mutant mouse model of amyotrophic lateral sclerosis. Dis Model Mech. 2014 Sep;7(9):1101‐9.
12: Parisi C, Arisi I, D’Ambrosi N, Storti AE, Brandi R, D’Onofrio M, Volonté C. Dysregulated microRNAs in amyotrophic
lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis. 2013 Dec 12;4:e959.
13: Parisi C, Volonté C. “MiRNAcles” in brain. CNS Neurol Disord Drug Targets. 2013 Sep;12(6):717‐8.
14: Apolloni S, Parisi C, Pesaresi MG, Rossi S, Cozzolino M, Volontè C, D’Ambrosi N. The NADPH oxidase pathway is dysregulated by P2X7 receptor in the SOD1‐G93A microglia model of Amyotrophic Lateral Sclerosis. J Immunol. 2013 190(10):5187‐95.
15: Volonté C, Parisi C, Burnstock G. Purinergic signalling: what is missing and needed next? The use of transgenic mice, crystallographic analysis and microRNA. CNS Neurol Disord Drug Targets 2012, 11:751‐767.
16: Ceci M, Welshhans K, Ciotti MT, Brandi R, Parisi C, Paoletti F, Pistillo L, Bassell GJ, Cattaneo A. RACK1 is a ribosome
scaffold protein for β‐actin mRNA/ZBP1 complex. PLoS One. 2012;7(4).
17: Caputo V, Sinibaldi L, Fiorentino A, Parisi C, Catalanotto C, Pasini A, Cogoni C, Pizzuti A. Brain derived neurotrophic
factor (BDNF) expression is regulated by microRNAs miR‐26a and miR‐26b allele‐specific binding. PLoS One.2011;6(12).
18: Parisi C, Giorgi C, Batassa EM, Braccini L, Maresca G, D’agnano I, Caputo V, Salvatore A, Pietrolati F, Cogoni C, Catalanotto C. Ago1 and Ago2 differentially affect cell proliferation, motility and apoptosis when overexpressed in SHSY5Y neuroblastoma cells. FEBS Lett. 2011;585(19):2965‐71.
19: Carlini F, Ridolfi B, Molinari A, Parisi C, Bozzuto G, Toccacieli L, Formisano G, De Orsi D, Paradisi S, Grober OM, Ravo M, Weisz A, Arcieri R, Vella S, Gaudi S. The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines. PLoS One. 2010;5(12).
Post-doctoral fellows:
Giulia Napoli giulia.napoli@ibbc.cnr.it
PhD student:
Valentina Pace, Noemi Panzironi
2014- AriSLA Call 2014 Pilot grant. PI, Chiara Parisi. MAMMALS, MiR-125b as Microglia Modifier for ALS.